These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 32552266

  • 1. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.
    Nishimura K, Hara R, Umebayashi H, Takei S, Iwata N, Imagawa T, Shimizu M, Tomiita M, Seko N, Kitawaki T, Yokota S.
    Mod Rheumatol; 2021 Jan; 31(1):226-234. PubMed ID: 32552266
    [Abstract] [Full Text] [Related]

  • 2. Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study.
    Iwata N, Nishimura K, Hara R, Imagawa T, Shimizu M, Tomiita M, Umebayashi H, Takei S, Seko N, Wakabayashi R, Yokota S.
    Mod Rheumatol; 2023 Nov 01; 33(6):1162-1170. PubMed ID: 36399020
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.
    Qiu L, Ma L, Xie Y, Jin J, Pan Y, Li S, Fan Z, Yu H.
    Pediatr Rheumatol Online J; 2024 Mar 19; 22(1):38. PubMed ID: 38504360
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial.
    Li C, Tang X, Zhou Z, Sun L, Lu M, Zhou W, Yang S, Zheng W, Yu H, Tan W, Zhang J, Zhang Y, Kong Y, Xu J.
    Clin Rheumatol; 2024 Nov 19; 43(11):3457-3467. PubMed ID: 39279018
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
    Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T.
    Lancet; 2008 Mar 22; 371(9617):998-1006. PubMed ID: 18358927
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
    Brunner HI, Quartier P, Alexeeva E, Constantin T, Koné-Paut I, Marzan K, Schneider R, Wulffraat NM, Chasnyk V, Tirosh I, Kallinich T, Kuemmerle-Deschner J, Wouters C, Lauwerys B, Nikishina I, Trachana M, Vougiouka O, Martini A, Lovell DJ, Levy J, Vritzali E, Ruperto N, Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheumatol; 2020 Dec 22; 72(12):2147-2158. PubMed ID: 32648697
    [Abstract] [Full Text] [Related]

  • 7. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T.
    J Rheumatol; 2014 Apr 22; 41(4):759-67. PubMed ID: 24634205
    [Abstract] [Full Text] [Related]

  • 8. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP.
    Arthritis Res Ther; 2017 Nov 22; 19(1):256. PubMed ID: 29166924
    [Abstract] [Full Text] [Related]

  • 9. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
    Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Ann Rheum Dis; 2018 Dec 22; 77(12):1710-1719. PubMed ID: 30269054
    [Abstract] [Full Text] [Related]

  • 10. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
    Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, Bader-Meunier B, Vastert SJ, Noseda E, D'Ambrosio D, Lecot J, Chakraborty A, Martini A, Chioato A, Paediatric Rheumatology International Clinical Trials Organisation.
    Arthritis Rheum; 2012 Feb 22; 64(2):557-67. PubMed ID: 21953497
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
    Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L, Lheritier K, Leon K, Karyekar CS, Speziale A.
    Clin Exp Rheumatol; 2018 Feb 22; 36(4):668-675. PubMed ID: 29533755
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
    Brunner HI, Ruperto N, Ramanan AV, Horneff G, Minden K, Calvo Penades I, Alexeeva E, Cleary G, Stern SM, Kone-Paut I, Maldonado Velázquez MDR, Rabinovich CE, Remesal A, Silva CA, Nikishina I, Zucchetto M, Brockwell L, Gordon O, Nagel S, De Benedetti F, PRINTO and PRCSG Investigators.
    Rheumatology (Oxford); 2024 Sep 01; 63(9):2535-2546. PubMed ID: 38552315
    [Abstract] [Full Text] [Related]

  • 13. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
    Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ, PRINTO, PRCSG.
    N Engl J Med; 2012 Dec 20; 367(25):2396-406. PubMed ID: 23252526
    [Abstract] [Full Text] [Related]

  • 14. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study.
    Quartier P, Alexeeva E, Constantin T, Chasnyk V, Wulffraat N, Palmblad K, Wouters C, I Brunner H, Marzan K, Schneider R, Horneff G, Martini A, Anton J, Wei X, Slade A, Ruperto N, Abrams K, Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheumatol; 2021 Feb 20; 73(2):336-346. PubMed ID: 32783351
    [Abstract] [Full Text] [Related]

  • 15. A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis.
    Hinze T, Kessel C, Hinze CH, Seibert J, Gram H, Foell D.
    Rheumatology (Oxford); 2021 Nov 03; 60(11):5165-5174. PubMed ID: 33576397
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of an early response-based tapering regimen of tocilizumab in children with systemic juvenile idiopathic arthritis.
    Dey S, Roy D, Sinhamahapatra P, Ghosh A.
    Int J Rheum Dis; 2024 May 03; 27(5):e15196. PubMed ID: 38769886
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.
    Alexeeva E, Krekhova E, Dvoryakovskaya T, Isaeva K, Chomakhidze A, Chistyakova E, Lomakina O, Denisova R, Mamutova A, Fetisova A, Gautier M, Vankova D, Kriulin I, Saygitov R.
    Front Pediatr; 2023 May 03; 11():1114207. PubMed ID: 36911042
    [Abstract] [Full Text] [Related]

  • 18. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
    Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C.
    Pediatr Rheumatol Online J; 2019 Aug 22; 17(1):57. PubMed ID: 31438986
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.
    Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, Iwata N, Murata T, Okafuji I, Miyoshi M, Onoe Y, Kawano Y, Kinjo N, Mori M, Mozaffarian N, Kupper H, Santra S, Patel G, Kawai S, Yokota S.
    Clin Rheumatol; 2012 Dec 22; 31(12):1713-21. PubMed ID: 23053683
    [Abstract] [Full Text] [Related]

  • 20. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
    Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Pérez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, Benedetti F, Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG).
    Rheumatology (Oxford); 2021 Oct 02; 60(10):4568-4580. PubMed ID: 33506875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.